NEW YORK ─ DiaSorin said on Thursday that it has received CE marking for its Liaison Testosterone xt test to measure testosterone in women and men, enabling its launch in European countries and others that accept the designation.
The Liaison Testosterone xt test enables the detection of fertility disorders, such as hypogonadism in men and hyperandrogenism in women, DiaSorin said. The company added that the test expands on its current fertility and endocrinology tests panel, which is available on the Liaison XL instrument and supports clinicians in the diagnosis and monitoring of disorders linked to the reproductive system.
The Saluggia, Italy-based diagnostic company said the Liaison Testosterone xt test, which runs on the Liaison XL instrument, is an evolution of its commercialized Liaison Testosterone test, which is a chemiluminescence immunoassay that measures testosterone in serum and plasma.